Lerodalcibep is a recombinant lipid-lowering biologic designed to inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9). By binding PCSK9, lerodalcibep helps increase the availability of low-density lipoprotein receptors (LDL receptors) on hepatocytes, thereby enhancing the removal of LDL cholesterol from the bloodstream.
Lerodalcibep is being developed for the management of hypercholesterolemia and cardiovascular risk, particularly in patients requiring additional LDL-cholesterol lowering.
Lerodalcibep is a specialized biological pharmaceutical ingredient requiring recombinant production, purification and extensive characterization.
Important quality attributes include identity, purity, molecular integrity, aggregation, charge variants, binding activity, biological potency, host-cell proteins, residual DNA, endotoxins, bioburden and sterility.
CAS Number: 2656799-04-1
Molecular Formula: Not applicable as a conventional small molecule
Molecular Weight: Approximately 85 kDa
Drug Class: Lipid-Lowering Biologic
Pharmacological Class: PCSK9 Inhibitor
Therapeutic Class: Lipid-Modifying Agent
Therapeutic Area: Cardiovascular / Metabolic
Lerodalcibep binds to PCSK9 and prevents PCSK9 from promoting degradation of hepatic LDL receptors.
Increased LDL-receptor availability allows the liver to remove more LDL cholesterol from circulation.
The mechanism results in:
Lerodalcibep is being developed for patients requiring substantial LDL-cholesterol reduction, including those with:
Specific indications depend on the applicable regulatory approval and product labeling.
Lerodalcibep is a long-acting PCSK9-binding biologic designed to provide sustained inhibition of circulating PCSK9.
Its long-acting characteristics support an extended dosing interval compared with many conventional lipid-lowering therapies.
Typical recombinant biologic manufacturing may involve:
Lerodalcibep quality evaluation may include:
Lerodalcibep drug substance and finished product should be stored according to validated stability data and approved product requirements, generally under controlled refrigerated conditions where specified. Protection from freezing, excessive heat and inappropriate light exposure is important for maintaining protein stability.
Lerodalcibep is relevant to research involving:
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 10 ppm |
| pH (1% Solution) | 2.0 – 4.0 |
| Individual Impurity | ≤ 0.5% |
| Total Impurities | ≤ 1.5% |
| Water Content | NMT 1.0% |